Chia-Hao Su

Dr. Chia-Hao Su

Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2013 in ACS Nano
Verified
Journal Article
Closed access
YCYi-Hsin Chien
Yi-Hsin Chien
YCYu-Lin Chou
Yu-Lin Chou
SWShu-Wen Wang
Shu-Wen Wang
SHShu-Ting Hung
Shu-Ting Hung
MLMin-Chiau Liau
Min-Chiau Liau
Chen-Sheng YehChen-Sheng Yeh
Chen-Sheng Yeh

18 October 2019 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
ZCZheng‐Zhe Chen
Zheng‐Zhe Chen
LWLiu‐Chun Wang
Liu‐Chun Wang
DMDivinah Manoharan
Divinah Manoharan
CLChin‐Lai Lee
Chin‐Lai Lee
LWLai‐Chin Wu
Lai‐Chin Wu
Chen-Sheng YehChen-Sheng Yeh
Chen-Sheng Yeh

11 July 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
STSuresh Thangudu
Suresh Thangudu
CSChia-Hao Su
Chia-Hao Su
Nanomaterial-mediated cancer therapeutics is a fast developing field and has been utilized in potential clinical applications. However, most effective therapies, such as photodynamic therapy (PDT) and radio therapy (RT), are strongly oxygen-dependent, which hinders their practical applications. Later on, several strategies were developed to overcome tumor hypoxia, such as oxygen carrier nanomaterials and oxygen generated nanomaterials. Among these, oxygen species generation on nanozymes, especially catalase (CAT) mimetic nanozymes, convert endogenous hydrogen peroxide (H2O2) to oxygen (O2) and peroxidase (POD) mimetic nanozymes converts endogenous H2O2 to water (H2O) and reactive oxygen species (ROS) in a hypoxic tumor microenvironment is a fascinating approach. The present review provides a detailed examination of past, present and future perspectives of POD mimetic nanozymes for effective oxygen-dependent cancer phototherapeutics.

20 December 2020 in Polymers
Verified
Journal Article
Open access
PDF file
STSuresh Thangudu
Suresh Thangudu
FCFong-Yu Cheng
Fong-Yu Cheng
CSChia-Hao Su
Chia-Hao Su
Noninvasive treatments to treat the brain-related disorders have been paying more significant attention and it is an emerging topic. However, overcoming the blood brain barrier (BBB) is a key obstacle to most of the therapeutic drugs to enter into the brain tissue, which significantly results in lower accumulation of therapeutic drugs in the brain. Thus, administering the large quantity/doses of drugs raises more concerns of adverse side effects. Nanoparticle (NP)-mediated drug delivery systems are seen as potential means of enhancing drug transport across the BBB and to targeted brain tissue. These systems offer more accumulation of therapeutic drugs at the tumor site and prolong circulation time in the blood. In this review, we summarize the current knowledge and advancements on various nanoplatforms (NF) and discusses the use of nanoparticles for successful cross of BBB to treat the brain-related disorders such as brain tumors, Alzheimer’s disease, Parkinson’s disease, and stroke.

20 February 2025 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
PMPravanjan Malla
Pravanjan Malla
YWYu-Ming Wang
Yu-Ming Wang
CSChia-Hao Su
Chia-Hao Su
The advent of nanozymes has revolutionized approaches to cancer diagnosis and therapy, introducing innovative strategies that address the limitations of conventional treatments. Nanozyme nanostructures with enzyme-mimicking catalytic abilities exhibit exceptional stability, biocompatibility, and customizable functions, positioning them as promising tools for cancer theranostics. By emulating natural enzyme reactions, nanozymes can selectively target and eradicate cancer cells, minimizing harm to adjacent healthy tissues. Nanozymes can also be functionalized with specific targeting ligands, allowing for the precise delivery and regulated release of therapeutic agents, improving treatment effectiveness and reducing adverse effects. However, issues such as biocompatibility, selectivity, and regulatory compliance remain critical challenges for the clinical application of nanozymes. This review provides an overview of nanozymes, highlighting their unique properties, various classifications, catalytic activities, and diverse applications in cancer treatments. The strategic oncological deployment of nanozymes could profoundly impact future advancements in personalized medicine, highlighting recent progress and prospective directions in enzyme-mimetic approaches for cancer treatment. This review summarizes an overview of nanozymes, highlighting their unique properties, various classifications, catalytic activities, and diverse applications in cancer treatments. Graphical Abstract

5 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
LWLiu-Chun Wang
Liu-Chun Wang
PCPei-Yu Chiou
Pei-Yu Chiou
YHYa-Ping Hsu
Ya-Ping Hsu
CLChin-Lai Lee
Chin-Lai Lee
CHChih-Hsuan Hung
Chih-Hsuan Hung
Chen-Sheng YehChen-Sheng Yeh
Chen-Sheng Yeh
Chemodynamic therapy (CDT) uses the Fenton or Fenton-like reaction to yield toxic ‧OH following H2O2 → ‧OH for tumoral therapy. Unfortunately, H2O2 is often taken from the limited endogenous supply of H2O2 in cancer cells. A water oxidation CoFe Prussian blue (CFPB) nanoframes is presented to provide sustained, external energy-free self-supply of ‧OH from H2O to process CDT and/or photothermal therapy (PTT). Unexpectedly, the as-prepared CFPB nanocubes with no near-infrared (NIR) absorption is transformed into CFPB nanoframes with NIR absorption due to the increased Fe3+-N ≡ C-Fe2+ composition through the proposed proton-induced metal replacement reactions. Surprisingly, both the CFPB nanocubes and nanoframes provide for the self-supply of O2, H2O2, and ‧OH from H2O, with the nanoframe outperforming in the production of ‧OH. Simulation analysis indicates separated active sites in catalyzation of water oxidation, oxygen reduction, and Fenton-like reactions from CFPB. The liposome-covered CFPB nanoframes prepared for controllable water-driven CDT for male tumoral mice treatments.